SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRC SciSparc Ltd.

Trading 05-19 11:06:18 EDT

4.55

+0.17

+3.77%

High4.68	Low4.40	Vol1.22K
Open4.41	D1 Closing4.38	Amplitude6.28%
Mkt Cap2.61M	Tradable Cap2.20M	Total Shares573.24K
T/O5.49K	T/O Rate0.25%	Tradable Shares485.10K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRC","market":"US","secType":"STK","nameCN":"SciSparc Ltd.","latestPrice":4.545,"timestamp":1779202657495,"preClose":4.38,"halted":0,"volume":1222,"delay":0,"changeRate":0.03767123287671234,"floatShares":485100,"shares":573243,"eps":98.07,"marketStatus":"Trading","change":0.165,"latestTime":"05-19 11:06:18 EDT","open":4.41,"high":4.675,"low":4.4,"amount":5492.206902,"amplitude":0.062785,"askPrice":4.69,"askSize":300,"bidPrice":4.4,"bidSize":105,"shortable":3,"etf":0,"ttmEps":98.07,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779220800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.38,"preHourTrading":{"tag":"盘前","latestPrice":4.4603,"preClose":4.38,"latestTime":"09:02 EDT","volume":1,"amount":4.4603,"timestamp":1779195769087,"change":0.0803,"changeRate":0.018333,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.38,"preClose":4.38,"latestTime":"17:21 EDT","volume":115,"amount":506.59,"timestamp":1779139306236,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.178832},"requestUrl":"/m/hq/s/SPRC/tweets","defaultTab":"tweets","newsList":[{"id":"2634254286","title":"SciSparc regains Nasdaq equity compliance, avoids delisting for now","url":"https://stock-news.laohu8.com/highlight/detail?id=2634254286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634254286?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:04","pubTimestamp":1778501067,"startTime":"0","endTime":"0","summary":"SciSparc received Nasdaq notice dated Jan. 12, 2026, citing noncompliance with continued listing rule 5550 due to stockholders’ equity below USD 2.5 million.Nasdaq staff also flagged failure to meet alternative continued listing thresholds tied to market value of listed securities at least USD 35 million or net income from continuing operations at least USD 500,000.Conditional compliance letter received May 7, 2026 said the company met rule 5550 based on its annual report for year ended Dec. 31, 2025 filed Apr. 29, 2026.Delisting risk remains if compliance evidence is not shown in the next periodic report filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL6t1nFt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631524659","title":"Scisparc FY25 net loss widens 94% to USD 12.18 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631524659","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631524659?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:07","pubTimestamp":1777496878,"startTime":"0","endTime":"0","summary":"SciSparc posted a net loss attributable to holders of Ordinary Shares of USD 12.18 million, worsening from USD 6.28 million.Revenue fell 35% to USD 856,000, due to operational difficulties that temporarily took Wellution offline from Amazon Marketplace.Operating loss widened 19% to USD 8.37 million.Financial expenses, net swung to an expense of USD 5.92 million from net income of USD 259,000, driven mainly by a USD 5.97 million impairment of loans granted to AutoMax.Outlook: cash and cash equivalents of USD 4.6 million are not sufficient to fund planned operations for at least a year beyond the filing date, raising substantial doubt about ability to continue as a going concern.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Lt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLQFDK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621819650","title":"Scisparc Director Alon Dayan Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2621819650","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621819650?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:01","pubTimestamp":1774296109,"startTime":"0","endTime":"0","summary":"Alon Dayan, a director at SciSparc, filed an initial statement of beneficial ownership reporting 3,651 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5lyY4w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620435264","title":"SciSparc Ltd. CEO and CFO Oz Adler Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620435264","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620435264?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864144,"startTime":"0","endTime":"0","summary":"SciSparc reported an initial statement of beneficial ownership by Oz Adler, an officer serving as CEO and CFO. Adler reported beneficial ownership of 11,058 ordinary shares held directly. Adler also reported a stock option for 6 ordinary shares with an exercise price of USD 21,294.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2l6j0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426449","title":"Scisparc Ltd. Director Moshe Revach Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426449","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426449?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864140,"startTime":"0","endTime":"0","summary":"Moshe Revach filed an initial statement of beneficial ownership as a director of SciSparc. The filing reported beneficial ownership of 3,651 ordinary shares. It also reported a stock option for 1 ordinary share with an exercise price of USD 21,294.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5Xv7sn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPRC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264487","title":"SciSparc Ltd. Director Amitay Weiss Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264487","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264487?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864138,"startTime":"0","endTime":"0","summary":"SciSparc reported an initial statement of beneficial ownership by director Amitay Weiss. The filing listed 11,058 ordinary shares beneficially owned. It also reported a stock option for 6 ordinary shares with an exercise price of USD 21,294.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4JWtnc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264465","title":"Scisparc Ltd. files Form 3 initial beneficial ownership statement for Director Lior Vider","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264465","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264465?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864126,"startTime":"0","endTime":"0","summary":"SciSparc reported an initial statement of beneficial ownership by director Lior Vider. The filing shows beneficial ownership of 3,651 ordinary shares. It also reports a stock option for 1 ordinary share with an exercise price of USD 21,294.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3XqSfb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPRC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619646878","title":"BRIEF-Scisparc Neurothera Labs- Clearmind Medicine Collaboration Leads To Patent Application For Depression Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2619646878","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619646878?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:21","pubTimestamp":1773663695,"startTime":"0","endTime":"0","summary":"BRIEF-Scisparc Neurothera Labs- Clearmind Medicine Collaboration Leads To Patent Application For Depression TherapyMarch 16 (Reuters) - Scisparc Ltd SPRC.O:SCISPARC: NEUROTHERA LABS- CLEARMIND MEDICIN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1SQRVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619733468","title":"NeuroThera Labs files Hong Kong patent application for MEAI-PEA depression therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2619733468","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619733468?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:20","pubTimestamp":1773663613,"startTime":"0","endTime":"0","summary":"NeuroThera Labs files Hong Kong patent application for MEAI-PEA depression therapy               NeuroThera, in which Scisparc holds a controlling interest of about 75%, reported that Clearmind filed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL6JgGK4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4585","LU2095319765.USD","BK4112","BK4007","SG9999014039.USD","IE00B64PRP62.GBP","SPRC","BK4588","BK4139","LU0314104364.USD","LU2210150020.SGD","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619146897","title":"Scisparc: Neurothera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2619146897","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619146897?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:20","pubTimestamp":1773663600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA1SQRVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619191760","title":"Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2619191760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619191760?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:45","pubTimestamp":1773402314,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nTUA71YFYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND","SPRC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619777158","title":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2619777158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619777158?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:59","pubTimestamp":1773331150,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life SciencesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL6N40014H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","SPRC","XOMO","IE0002270589.USD","LU0175139822.USD","BMBL","LU0320765646.SGD","SG9999014898.SGD","PCRX","WLTH","SG9999014906.USD","MUR","XOMZ","GYRE","UAL","NTRA","OWL","INTS","DKS","DAL","CASH","BX","DG","JBL","RPID","LU1116320737.USD","LUV","TBBK","MOS","DOW","MELI","CUBI","AAL","CE","AALG","KZR","SM","KKR","KMLI","NOG","BBW","GIII","LU1868837565.USD","CF","GFS","XOMX","ARES"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618013106","title":"BUZZ-SciSparc jumps as unit files patent for obesity, fatty liver treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2618013106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618013106?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317117,"startTime":"0","endTime":"0","summary":"BUZZ-SciSparc jumps as unit files patent for obesity, fatty liver treatment** Shares of Israel-based drug developer SciSparc SPRC.O surge 34% to $5.21 premarket** Co says its majority-owned unit NeuroThera Labs filed an international patent for a new combination drug aimed at obesity and metabolic liver disease** Treatment combines MEAI and PEA, developed with Clearmind Medicine CMND.O, co says** Targets obesity and MASLD, a condition where excess fat builds up in the liver and disrupts metabolism; MASLD was earlier known as fatty liver disease - SPRC** Co says therapy could be a safer, cheaper alternative to GLP-1 weight-loss drugs, which can cause side effects** Shares up ~82% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL4N40016A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPRC","CMND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131671","title":"SciSparc-Controlled NeuroThera Labs Publishes PCT Patent for MEAI-PEA Weight Loss and MASLD Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131671?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:55","pubTimestamp":1773316529,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL7h30yC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","SPRC","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131982","title":"Scisparc: Neurothera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131982","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131982?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:55","pubTimestamp":1773316503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA5FMTXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618955003","title":"SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum","url":"https://stock-news.laohu8.com/highlight/detail?id=2618955003","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618955003?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:38","pubTimestamp":1773149890,"startTime":"0","endTime":"0","summary":"NeuroThera Labs, in which SciSparc (SPRC)holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-says-neurothera-labs-agrees-to-acquire-majority-stake-in-cliniquantum-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-says-neurothera-labs-agrees-to-acquire-majority-stake-in-cliniquantum-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618995561","title":"Scisparc Ltd - Neurothera to Buy 56,375 Cliniquantum Shares Representing 54.01% Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2618995561","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618995561?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:28","pubTimestamp":1773149280,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA89RP74:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618647955","title":"Scisparc Ltd - Selling Shareholders May Receive Earn-Out Payments up to $2.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647955?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:28","pubTimestamp":1773149280,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA89RP74:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SPRC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618195569","title":"Scisparc: Subsidiary Neurothera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in Cliniquantum, Innovator in Quantum-Based Clinical Trails","url":"https://stock-news.laohu8.com/highlight/detail?id=2618195569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618195569?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:28","pubTimestamp":1773149280,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA89RP74:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRC","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618616955","title":"Press Release: SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails","url":"https://stock-news.laohu8.com/highlight/detail?id=2618616955","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618616955?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:28","pubTimestamp":1773149280,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, March 10, 2026  -- SciSparc Ltd.  , today announced that NeuroThera Labs Inc.  , a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement , between NeuroThera, CliniQuantum Ltd.  and the Selling Shareholders  to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ  on a fully diluted basis immediately prior to the closing of the transaction . CliniQ is a quantum technology company holding patents from Ramot at the Tel Aviv University,  in the field of quantum simulation and quantum Monte Claro.CliniQ develops a next-generation platform to transform clinical trials with the power of quantum computing. Its aim is to unlock insights hidden in massive, complex datasets to design smarter, faster, and more adaptive studies.Closing of the Transaction is expected ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","SPRC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scisparc.com","stockEarnings":[{"period":"1week","weight":-0.2772},{"period":"1month","weight":-0.009},{"period":"3month","weight":-0.1551},{"period":"6month","weight":-0.8022},{"period":"1year","weight":-0.9266},{"period":"ytd","weight":-0.6422}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.075328},{"month":2,"riseRate":0.2,"avgChangeRate":-0.14034},{"month":3,"riseRate":0,"avgChangeRate":-0.320237},{"month":4,"riseRate":0.4,"avgChangeRate":0.283936},{"month":5,"riseRate":0.4,"avgChangeRate":-0.13187},{"month":6,"riseRate":0,"avgChangeRate":-0.156179},{"month":7,"riseRate":0,"avgChangeRate":-0.243864},{"month":8,"riseRate":0,"avgChangeRate":-0.467442},{"month":9,"riseRate":0.25,"avgChangeRate":0.236982},{"month":10,"riseRate":0.75,"avgChangeRate":0.077569},{"month":11,"riseRate":0.5,"avgChangeRate":0.007929},{"month":12,"riseRate":0.25,"avgChangeRate":-0.09099}],"exchange":"NASDAQ","name":"SciSparc Ltd.","nameEN":"SciSparc Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SciSparc Ltd.,SPRC,SciSparc Ltd.股票,SciSparc Ltd.股票老虎,SciSparc Ltd.股票老虎国际,SciSparc Ltd.行情,SciSparc Ltd.股票行情,SciSparc Ltd.股价,SciSparc Ltd.股市,SciSparc Ltd.股票价格,SciSparc Ltd.股票交易,SciSparc Ltd.股票购买,SciSparc Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction